Latest & greatest articles for oxybutynin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on oxybutynin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on oxybutynin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for oxybutynin

1. Oxybutynin

Oxybutynin Top results for oxybutynin - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for oxybutynin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Desmopressin versus Oxybutynin for Nocturnal Enuresis in Children in Bandar Abbas: A Randomized Clinical Trial.

Desmopressin versus Oxybutynin for Nocturnal Enuresis in Children in Bandar Abbas: A Randomized Clinical Trial. 27123229 2016 04 28 2016 04 28 2017 02 21 8 3 2016 Mar Electronic physician Electron Physician Desmopressin versus Oxybutynin for Nocturnal Enuresis in Children in Bandar Abbas: A Randomized Clinical Trial. 2187-93 10.19082/2187 Nocturnal enuresis is among the most common disorders in children. Several pharmacological and non-pharmacological treatments are available for nocturnal (...) enuresis. Studies for reaching the best pharmacological treatment for this disorder are continuing. To compare the effectiveness and safety of Desmopressin and oxybutynin for treatment of nocturnal enuresis in children from Bandar Abbas in 2014. This randomized controlled trial was conducted in 2014 and participants included 66 children with nocturnal enuresis who were more than 5 years old. Patients were randomly assigned into two groups. The first group received 120 microgram Desmopressin daily for 2 months

Electronic physician2016 Full Text: Link to full Text with Trip Pro

4. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom Hart WM, Abrams P, Munro V, Retsa P (...) , Nazir J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study evaluated the cost-effectiveness of solifenacin compared with oxybutynin immediate-release for treating overactive bladder. The authors concluded that the solifenacin

NHS Economic Evaluation Database.2014

5. SENIOR: Solifenacin (VESICARE) vs Oxybutynin (DITROPAN) vs Placebo Use in Elderly People with Mild Cognitive Impairment (MCI)

SENIOR: Solifenacin (VESICARE) vs Oxybutynin (DITROPAN) vs Placebo Use in Elderly People with Mild Cognitive Impairment (MCI)

RxFiles2013

7. Anturol (oxybutynin), 3% gel

Anturol (oxybutynin), 3% gel Drug Approval Package: ANTUROL NDA #202513 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - ANTUROL (oxybutynin), 3% gel Company: Antares Pharma, Inc. Application No.: 202513 Approval Date: 12/07/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: June 26, 2012

FDA - Drug Approval Package2012

8. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service (...) The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service Cardozo L, Thorpe A, Warner J, Sidhu M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed

NHS Economic Evaluation Database.2010

9. Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events

Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events Boudreau R, Cimon K, Cunningham J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boudreau R, Cimon K (...) , Cunningham J. Oxybutynin, tolterodine, and darifenacin: review of cognitive adverse events . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions Most of the studies concluded that cognitive function was not affected by taking oxybutynin, tolterodine, or darifenacin. All of the studies were short-term which may not reflect the typical patient on these medications. Three FDA advisories have been issued which stated that there have been reports of cognitive

Health Technology Assessment (HTA) Database.2009

10. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence

Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence 18410326 2008 05 05 2008 05 21 2013 11 21 1532-5415 56 5 2008 May Journal of the American Geriatrics Society J Am Geriatr Soc Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents (...) with urge urinary incontinence. 862-70 10.1111/j.1532-5415.2008.01680.x Determine the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence. Randomized, double-blinded, placebo-controlled trial. Twelve skilled nursing homes. Fifty women aged 65 and older with urge incontinence and cognitive impairment. Four-week treatment with once-daily oral extended-release oxybutynin 5 mg or placebo

EvidenceUpdates2008

11. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review

Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review Guerra LA, Moher D, Sampson M, Barrowman N, Pike J, Leonard M CRD summary The review concluded that, whilst intravesical oxybutynin was a potential alternative therapy for children with neurogenic (...) bladder refractory to oral oxybutynin, or those who experience severe side effects with oral oxybutynin, there was insufficient evidence to recommend this treatment. The authors' conclusions are suitably cautious and reflect the limited evidence base. Authors' objectives To determine the effectiveness and tolerability of intravesical oxybutynin in children with poorly compliant neurogenic bladder. Searching The authors searched MEDLINE, EMBASE, LILACS, the Cochrane Library, CINAHL, ProQuest Nursing

DARE.2008

13. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder

Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder Getsios D, Caro J J, Ishak K J, El Hadi W, Payne K Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two pharmacological treatments for overactive bladder (OAB) were examined. These were the new extended-release (XL) formulation of oxybutynin (10 mg/day) and immediate-release (IR) tolterodine (4 mg/day). Type of intervention

NHS Economic Evaluation Database.2004

14. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria

Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment (...) of overactive bladder in the UK, France and Austria Guest J F, Abegunde D, Ruiz F J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of controlled-release (CR) oxybutynin (at a dose titrated up to 10 mg/day) for the treatment

NHS Economic Evaluation Database.2004

15. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence

Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence Hughes D A, Dubois D Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four treatments for patients with urge incontinence were examined. The specific treatments were oxybutynin extended-release (Oxy-ER), tolterodine extended-release (Tol-ER), oxybutynin immediate-release (Oxy-IR) and tolterodine immediate-release (Tol-IR). Type

NHS Economic Evaluation Database.2004

16. Oxybutynin extended release and tolterodine immediate release: a health economic comparison

Oxybutynin extended release and tolterodine immediate release: a health economic comparison Oxybutynin extended release and tolterodine immediate release: a health economic comparison Oxybutynin extended release and tolterodine immediate release: a health economic comparison Getsios D, Caro J J, Ishak K J, El-Hadi W, Payne K, O'Connel M, Albrecht D, Feng W, Dubois D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of oxybutynin extended release (XL) and tolterodine immediate release (IR) for the treatment of overactive bladder. The doses used were 10 mg/day (oxybutynin) and 4 mg/day (tolterodine), respectively. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population

NHS Economic Evaluation Database.2004

17. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis

Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis Harvey M A, Baker K, Wells G A Authors' objectives To compare tolterodine with oxybutynin in the treatment of urge incontinence. Searching The following sources were searched: MEDLINE from 1966 to March 2000; EMBASE from (...) 1988 to March 2000; HealthSTAR from 1974 to January 2000; CINAHL from 1982 to December 1999; Current Contents from 1998 to March 2000; the Cochrane Controlled Trials Register (Issue 4, 1999); and Dissertation Abstracts from 1990 to 1996. The search terms included 'tolterodine', 'oxybutynin', 'Detro', 'Detrusitol', 'PNU 200577' and 'PNU 200583'. Specialist journals, meeting abstracts and the bibliographies of the retrieved articles were searched manually. In addition, the relevant pharmaceutical

DARE.2001

18. Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladder

Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladder Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladder Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladder Ho C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ho C. Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive (...) bladder. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2001: 4 Authors' objectives To summarise the available evidence on transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladders. Authors' conclusions - The oxybutynin patch is a transdermal delivery system, which releases the drug oxybutynin through the skin for the management of overactive bladder. - Limited evidence suggests that transdermal delivery of oxybutynin over a short period of time may have

Health Technology Assessment (HTA) Database.2001